SPOTLIGHT: India's Lupin buying Japanese generics maker

Apparently all of pharma is looking to Asia--even the Asians. India's Lupin paid $60 million for a 79 percent interest in the Japanese pharma Kyowa to establish a "beachhead in the second-largest pharmaceutical market." Release

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.